NEU 0.35% $20.17 neuren pharmaceuticals limited

A very short duration that still showed an extremely high safety...

  1. 434 Posts.
    lightbulb Created with Sketch. 146
    A very short duration that still showed an extremely high safety profile at high doses. We just need to repeat this and judging by the retts community excitement for trof, we are already home and hosed.

    I was reading a q and a and one of the questions was asking if patients can still take trof if it fails P3 but they were partaking in the trial. Retts community need this.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.